Please one a plus sign (+) is		persons are required		rademark Offi	PTO/SB/21 (05-03) use through 04/30/2003. OMB 0651-0031 ice; U.S. DEPARTMENT OF COMMERCE ass it displays a valid OMB control number.	
	32		Application Number	10/716,84	16	
ADEMARK	NOMETTAL		Filing Date	Novembe	er 18, 2003	
IRANSMITTAL			First Named Inventor	KHOSLA	, CHAITAN	
FORM		Group Art Unit				
(to be used for all correspondence after initial filing)			Examiner Name			
Total Number o	Total Number of Pages in This Submission 3 + REFS.		Attorney Docket Number	STAN-258CIP		
		ENCLOSUR	ES (check all that apply)		
Extension of T Express Abance Information Dist Certified Copy Documents Response to M Incomplete Ap	ched Reply al s/declaration(s) time Request donment Request sclosure Statement of Priority tissing Parts/	Control Cont	ng-related Papers n to Convert to a onal Application of Attorney, Revocation e of Correspondence	1. 2.	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Copy of PTO/SB/08a from parent Postcard	
Signing Attorney/Agent	SIGNA PAMELA J. SHERV		ICANT, ATTORNEY, O	R AGENT		
(Reg. No.) Signature	DOLOGIO IL LED GI					
Date February 24, 2004				-		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL LABEL NO. EV333998242US

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV333998242US

BADEMATION DISCLOSURE STATEMENT

Address to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	STAN-258CIP		
First Named Inventor	KHOSLA, CHAITAN		
Application Number	10/716,846		
Confirmation No.			
Filing Date	November 18, 2003		
Group Art Unit			
Examiner Name			
Title: "DRUG THERAPY FOR CELIAC SPRUE"			

Sir:

4.

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-258CIP may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Registration No. 36,677

Date: _____February 24, 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\PATTSY97-2\LETTERS\FFISB41A.doc

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 10/716,846 INFORMATION DISCLOSURE Filing Date November 18, 2003 STATEMENT BY APPLICANT First Named Inventor KHOSLA, CHAITAN **Art Unit Examiner Name** (use as many sheets as necessary) Sheet of 1 **Attorney Docket Number** STAN-258CIP 1

•			U.S. PATENT D	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials'	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
		US-			
		US-		1	

		FOREIG	N PATENT DO	UMENTS		
Examiner Initials'	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	NO.	Country Code ³ –Number ⁴ –Kind Code ⁵ (if known)	IVIIVI-DD-TTTT			T ⁶
		AHNEN et al., INTESTINAL AMI INTRACELLUALAR MEMBRAN				
0.00		ARENTZ-HANSEN et al., THE IN ADULT CELIAC DISEASE IS FO TARGETED BY TISSUE TRANS	CUSED ON A	SINGLE DEAMIDATEL	GLUTAMINE	
		BORDUSA et al., THE SPECIFICITY OF PROLYL ENDOPEPTIDASE FROM FLAVOBACTERIUM MENINGOSEPTUM: MAPPING THE S' SUBSITES BY POSITIONAL SCANNING VIA ACYL TRANSFER, Bioorg. Med. Chem., (1998), 6: 1775-80				
	LAHTEENOJA et al., LOCAL CHALLENGE ON ORAL MUCOSA WITH AN α-GLIADIN RELATED SYNTHETIC PEPTIDE IN PATIENTS WITH CELIAC DISEASE, Am. J. Gastroenterol., (2000), 95: 2880					
		SCHUPPAN, DETLEF, SPECIAL REPORTS AND REVIEWS CURRENT CONCEPTS OF CELIAC DISEASE PATHOGENESIS. Gastroenterology, (2000), 119: 234-42 WIESER, HERBERT, THE PRECIPITATING FACTOR IN COELIAC DISEASE, Baillieres Clin Gastroenterol, (1995). 9(2):191-207 YOSHIMOTO et al., PROLYL ENDOPEPTIDASE FROM FLAVOBACTERIUM MENINGOSEPTICUM: CLONING AND SEQUENCING OF THE ENZYME GENE, J. Biochem., (1991), 110: 873-8				

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450.